Astria Therapeutics, Inc. ( (ATXS) ) has released its Q3 earnings. Here is a breakdown of the information Astria Therapeutics, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Astria Therapeutics, Inc. is a biopharmaceutical company dedicated to developing transformative therapies for allergic and immunologic diseases, with a focus on hereditary angioedema and atopic dermatitis. In its third quarter 2025 financial report, Astria Therapeutics announced its acquisition by BioCryst Pharmaceuticals, expected to finalize in early 2026, alongside updates on its key drug development programs. The company highlighted significant progress in its clinical trials, particularly with navenibart, which showed promising results in reducing attack rates in hereditary angioedema patients. Additionally, Astria’s STAR-0310 program demonstrated potential as a leading treatment for atopic dermatitis. Financially, Astria reported a net loss of $31.6 million for the quarter, with increased research and development expenses attributed to ongoing clinical trials. Looking ahead, Astria remains optimistic about its strategic direction and continued advancements in its drug development pipeline, supported by the upcoming merger with BioCryst.